PharmaShots | Incisive News in 3 Shots

Subscribe Now

Biocytogen

Biocytogen Partners with Acepodia to Develop Bispecific Antibody and Dual-Payload ADCs to Treat Complex Tumors

Biocytogen Partners with Acepodia to Develop Bispecific Antibody and Dual-Payload ADCs to Treat Complex Tumors

January 8, 2025

Biocytogen and Gilead Partner to Select and Develop Therapeutic Targets for the Treatment of Multiple Diseases

Biocytogen and Gilead Partner to Select and Develop Therapeutic Targets for the Treatment of Multiple Diseases

February 21, 2024

Biocytogen and Neurocrine Biosciences Sign an Antibody Evaluation and Option Agreement

Biocytogen and Neurocrine Biosciences Sign an Antibody Evaluation and Option Agreement

December 20, 2023

Biocytogen Entered into a License Agreement with Pheon Therapeutics to Develop Antibody-Drug Conjugate for Cancer

Biocytogen Entered into a License Agreement with Pheon Therapeutics to Develop Antibody-Drug Conjugate for Cancer

July 6, 2023

Biocytogen’s Subsidiary Eucure Biopharma Signs an Exclusive License Agreement with Chipscreen’s Holding Subsidiary Chipscreen NewWay for YH008

Biocytogen’s Subsidiary Eucure Biopharma Signs an Exclusive License Agreement with Chipscreen’s Holding Subsidiary Chipscreen NewW...

February 28, 2023

Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies

Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies

November 29, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us